Common blood pressure medication associated with poorer kidney outcomes in type 2 diabetes

by European Renal Association

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Associate Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

New research presented at the 63rd ERA Congress suggests that a widely used class of blood pressure medications may be associated with poorer kidney outcomes in people with type 2 diabetes (T2D), even among patients already receiving modern kidney-protective treatments.

Dihydropyridine calcium-channel blockers (DCCBs) are a commonly prescribed class of blood pressure medications that work by relaxing blood vessels and are frequently used as second-line therapies in people with diabetic kidney disease (DKD).

Researchers found that patients taking DCCBs alongside standard therapies had a significantly higher risk of major adverse kidney events, compared with those receiving alternative blood pressure treatments.

DKD is one of the leading causes of kidney failure worldwide. It develops when persistently high blood sugar damages the small blood vessels in the kidneys, gradually reducing their ability to filter waste from the blood. Controlling blood pressure is a cornerstone of treatment, as high blood pressure accelerates this damage.

In recent years, two classes of medication have transformed care for people with DKD: renin-angiotensin system (RAS) inhibitors, which lower blood pressure and reduce pressure within the kidney's filtering units, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed as diabetes drugs but now recognized for their kidney-protective effects and ability to reduce the risk of kidney failure. Together, these therapies now form part of the standard of care for most patients with DKD.

The study analyzed data from 31,031 adults with T2D between 2016 and 2021. All patients were receiving both RAS and SGLT2 inhibitors as part of their care. Among the participants, 12,172 (39.2%) were also taking DCCBs, while 18,859 (60%) were receiving other antihypertensive treatments. Patients were followed for a median of approximately three and a half years.

After adjusting for differences in baseline clinical and demographic characteristics, researchers found that DCCB use was associated with a 33% higher risk of a major adverse kidney event (R 1.33, 95%, CI 1.03–1.73). These events were defined as either a substantial decline in kidney filtration capacity—a drop of 40% or more in estimated glomerular filtration rate (eGFR), the standard measure of kidney function—or progression to end-stage kidney disease requiring dialysis or transplantation.

"DCCBs are widely used as second-line blood pressure treatments in patients with DKD," said Dr. Timna Agur, lead author of the study. "Our findings raise important questions about whether these medications are always the best option for patients already receiving modern kidney-protective therapies."

The researchers believe the findings may be explained by the way DCCBs affect blood flow within the kidney. In DKD, the kidneys are already exposed to increased pressure and hyperfiltration, a state in which the filtering units are working under excessive strain.

Researchers suggest DCCBs may preferentially relax the blood vessels carrying blood into the kidney's filtering units without having the same effect on vessels carrying blood out, potentially increasing pressure within these structures and contributing to ongoing kidney damage.

"We initially thought the kidney-protective effects of SGLT2 inhibitors might counterbalance the potential harms associated with DCCBs," said Dr. Agur. "However, the increased risk of kidney disease progression appeared to persist even in this group."

The researchers caution that the study was observational in nature and cannot establish direct causation. Nevertheless, they argue the results are clinically significant given how commonly DCCBs are prescribed in this patient population.

"Further prospective studies and randomized controlled trials are needed to confirm these observations and better define the safest blood pressure treatment strategies for patients with DKD," concluded Dr. Agur. "However, given how commonly these medications are prescribed, any increase in kidney risk could have important implications for large numbers of patients with DKD."

More information

Agur T, et al. DCCB Therapy and Risk of CKD Progression in Type 2 Diabetes on RASi and SGLT2i.

Key medical concepts

Diabetic Kidney ProblemsSodium-Glucose Transporter 2 InhibitorsDiabetes Type 2

Clinical categories

NephrologyEndocrinology Provided by European Renal Association Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Common blood pressure medication associated with poorer kidney outcomes in type 2 diabetes (2026, June 4) retrieved 4 June 2026 from https://medicalxpress.com/news/2026-06-common-blood-pressure-medication-poorer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.